ArticleEuropean journal of heart failure2025
A U-shaped relationship between left ventricular ejection fraction and risk of worsening heart failure.
Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Beyond the Liver: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Associated 35% Higher Risk of Clinically Diagnosed Heart Failure With Preserved Ejection Fraction (HFpEF).Current cardiology reports · 2026Pooled it
- Supranormal Ejection Fraction as a Clinical Red Flag: Differentiating Hemodynamic Stress From Intrinsic Cardiomyopathy in Heart Failure.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Phenotyping Heart Failure: Looking Beyond Left Ventricular Ejection Fraction.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Heart Failure with Supranormal Ejection Fraction: An Emerging High-Risk Phenotype Within the Preserved Ejection Fraction Spectrum-A Systematic Review.Journal of clinical medicine · 2026Review
- Article
- Prognostic value of potential energy derived from noninvasive pressure-volume loop analysis in heart failure with preserved ejection fraction.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsLeft ventricular ejection fraction (LVEF) is a key measure of cardiac function. While prior studies showed a U-shaped relationship between LVEF and mortality, its association with worsening heart failure (HF) remains unclear. We aimed to evaluate the association between the full spectrum of LVEF and the risk of worsening HF. METHODS AND
resultsWe analysed data from 93 694 consecutive participants (median age 62 years [interquartile range: 50-76 years], 51.4% men) undergoing echocardiography at a tertiary medical centre. LVEF, measured by biplane Simpson's method, was categorized into 5% intervals from <20% to ≥70%. The primary outcome was a composite of all-cause mortality or worsening HF, while the secondary outcomes included all-cause mortality, cardiovascular death, and worsening HF. The primary outcome occurred in 32 398 (34.6%) participants over a median follow-up of 8.3 years. A U-shaped relationship between LVEF and the primary outcome was observed, with a nadir at 60-70% and an increased risk when LVEF was ≥70% [adjusted hazard ratio (aHR) 1.12; 95% confidence interval (CI) 1.06-1.18]. Similar patterns were observed for the secondary outcomes. Participants with LVEF ≥70% also had a higher risk of worsening HF (aHR 1.13, 95% CI 1.03-1.23). This U-shaped association was consistent across subgroups stratified by age, sex, hypertension, and diabetes, and was observed for both incident and recurrent HF events.
conclusionsLeft ventricular ejection fraction demonstrated a U-shaped association with worsening HF, with the lowest risk at 60-70%. Supranormal LVEF (≥70%) identified a high-risk phenotype, underscoring the need for tailored management strategies for this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.